Literature DB >> 16039909

T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner.

Giuliana Vallanti1, Rossella Lupo, Maurizio Federico, Fulvio Mavilio, Chiara Bovolenta.   

Abstract

The viral infectivity factor (Vif) is an essential component of the HIV-1 infectious cycle. Vif counteracts the action of the cytidine deaminase APOBEC3G (AP3G), which confers nonimmune antiviral defense against HIV-1 to T lymphocytes. Disabling or interfering with the function of Vif could represent an alternative therapeutic approach to AIDS. We have expressed a natural mutant of Vif, F12-Vif, in a VSV-G-pseudotyped lentiviral vector under the Tat-inducible control of the HIV-1 LTR. Conditional expression of F12-Vif prevents replication and spreading of both CXCR4 and CCR5 strains of HIV-1 in human primary T lymphocyte and T cell lines. T cells transduced with F12-Vif release few HIV-1 virions and with reduced infectivity. Several lines of evidence indicate that HIV-1 interference requires the presence of both wild-type and F12-Vif proteins, suggesting a dominant-negative feature of the F12-Vif mutant. Surprisingly, however, the F12-Vif-mediated inhibition does not depend on the reestablishment of the AP3G function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039909     DOI: 10.1016/j.ymthe.2005.05.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

1.  HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication.

Authors:  Taisuke Izumi; Katsuhiro Io; Masashi Matsui; Kotaro Shirakawa; Masanobu Shinohara; Yuya Nagai; Masahiro Kawahara; Masayuki Kobayashi; Hiroshi Kondoh; Naoko Misawa; Yoshio Koyanagi; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-11       Impact factor: 11.205

2.  Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.

Authors:  Robert C Walker; Mohammad A Khan; Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Klaus Strebel
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

4.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

5.  Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.

Authors:  Eri Miyagi; Sarah Welbourn; Sayaka Sukegawa; Helena Fabryova; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

6.  Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles.

Authors:  Sharon Aviran; Priya S Shah; David V Schaffer; Adam P Arkin
Journal:  PLoS Comput Biol       Date:  2010-08-12       Impact factor: 4.475

7.  Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.

Authors:  Claudia Arenaccio; Chiara Chiozzini; Sandra Columba-Cabezas; Francesco Manfredi; Maurizio Federico
Journal:  Retrovirology       Date:  2014-06-12       Impact factor: 4.602

Review 8.  Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.

Authors:  Arun K Nalla; Grant D Trobridge
Journal:  Biomedicines       Date:  2016-03-29

9.  Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Authors:  Alexandra Kataropoulou; Chiara Bovolenta; Amalia Belfiore; Sonia Trabatti; Anna Garbelli; Simona Porcellini; Rossella Lupo; Giovanni Maga
Journal:  Nucleic Acids Res       Date:  2009-04-15       Impact factor: 16.971

10.  Heterogeneity of signal transducer and activator of transcription binding sites in the long-terminal repeats of distinct HIV-1 subtypes.

Authors:  Andrea Crotti; Giulia D Chiara; Silvia Ghezzi; Rossella Lupo; Rienk E Jeeninga; Elio Liboi; Patricia M-J Lievens; Elisa Vicenzi; Chiara Bovolenta; Ben Berkhout; Guido Poli
Journal:  Open Virol J       Date:  2007-10-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.